Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGB | P11216 | 7/20 | 0.70 |
| ▸ | GAA | P10253 | 1/20 | 0.70 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 3/20 | 0.53 |
| ▸ | CA1 | P00915 | 3/20 | 0.53 |
| ▸ | CA2 | P00918 | 3/20 | 0.53 |
| ▸ | CA9 | Q16790 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12510566 | 1.00 | PYGB (0.70) | PYGBGAAAKR1B1TSHRCA12 | |
| SCHEMBL7150986 | 1.00 | PYGB (0.70) | PYGBGAAAKR1B1TSHRCA12 | |
| SCHEMBL488948 | 1.00 | PYGB (0.70) | PYGBGAAAKR1B1TSHRCA12 | |
| SCHEMBL1582415 | 1.00 | PYGB (0.70) | PYGBGAAAKR1B1TSHRCA12 | |
| SCHEMBL7150977 | 1.00 | PYGB (0.70) | PYGBGAAAKR1B1TSHRCA12 | |
| SCHEMBL468706 | 0.98 | PYGB (0.67) | PYGBGAAAKR1B1TSHRCA12 | |
| SCHEMBL7149670 | 0.98 | PYGB (0.67) | PYGBGAAAKR1B1TSHRCA12 | |
| SCHEMBL31477900 | 0.88 | PYGB (0.64) | PYGBGAAAKR1B1CA12CA1 | |
| SCHEMBL4307948 | 0.86 | PYGB (0.62) | PYGBGAA | |
| SCHEMBL9302995 | 0.86 | CA1 (0.60) | PYGBGAACA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110150984-A1 | METHODS OF INCREASING THE BIOAVAILABILITY AND/OR CELLULAR UPDATE OF DRUGS | HET NEDERLANDS KANKER INSTITUUT (NL) | 2011-06-23 | — | — | US | disclosed |
| US-7915227-B2 | Pharmaceutical formulations employing short-chain sphingolipids and their use | HET NEDERLANDS KANKER INSTITUUT (NL) | 2011-03-29 | — | — | US | disclosed |
| EP-1686959-B1 | PHARMACEUTICAL FORMULATIONS EMPLOYING SHORT-CHAIN SPHINGOLIPIDS AND THEIR USE | HET NL KANKER I THE NETHERLAND (NL) | 2009-06-24 | — | — | EP | disclosed |
| US-20090041740-A1 | CANCER TREATMENT BY METABOLIC MODULATIONS | ENGENE, INC. (CA) | 2009-02-12 | — | — | US | disclosed |
| US-20070082855-A1 | Pharmaceutical formulations employing short-chain sphingolipids and their use | HET NEDERLANDS KANKER INSTITUUT (NL) | 2007-04-12 | — | — | US | disclosed |
| US-20070082855-A1 | Pharmaceutical formulations employing short-chain sphingolipids and their use | HET NEDERLANDS KANKER INSTITUUT (NL) | 2007-04-12 | — | — | US | disclosed |
| WO-2006043036-A2 | TREATMENT OF DIABETES | THE UNIVERSITY OF NEWCASTLE (GB) | 2006-04-27 | — | — | WO | disclosed |
| US-20050202559-A1 | Cancer treatment by metabolic modulations | HERCULES CAPITAL, INC. | 2005-09-15 | — | — | US | disclosed |
| EP-1556088-A2 | COMPOSITIONS FOR CANCER TREATMENT | Engene, Inc. (CA) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004039412-A2 | COMPOSITIONS FOR CANCER TREATMENT | ENGENE, INC. (CA) | 2004-05-13 | — | — | WO | disclosed |
| US-20020031816-A1 | METHOD OF INHIBITION OF HUMAN GLYCOGEN PHOSPHORYLASE | PFIZER PRODUCTS INC. | 2002-03-14 | — | — | US | disclosed |
| EP-0978279-A1 | Inhibitors of human glycogen phosphorylase | Pfizer Products Inc. (US) | 2000-02-09 | — | — | EP | disclosed |
| WO-1995003809-A2 | USE OF GLUCOKINASE INHIBITORS FOR THE MANUFACTURE OF A MEDICAMENT FOR TREATING TUMOURS | ISIS INNOVATION LIMITED (GB) | 1995-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110150984-A1 | METHODS OF INCREASING THE BIOAVAILABILITY AND/OR CELLULAR UPDATE OF DRUGS | NPC1L1, SGMS2, SGMS1 | PYGB 1298/4885GAA 284/4885AKR1B1 1179/4885 |
| US-20070082855-A1 | Pharmaceutical formulations employing short-chain sphingolipids and their use | SGMS1, SGMS2, CERT1 | PYGB 1998/4885GAA 544/4885AKR1B1 2451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.